DJ Sartorius Stedim Biotech: Information on Document Availability
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech: Information on Document Availability
16-Feb-2024 / 09:23 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Aubagne, February 16, 2024
Sartorius Stedim Biotech: Information on Document Availability
Sartorius Stedim Biotech Group's Universal Registration Document 2023 is now available at:
https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations/
news-financial-publications
It contains the following information:
- Business development for fiscal 2023 and the 2024 forecast for the Sartorius Stedim Biotech Group
- Consolidated financial statements for the year ended December 31, 2023
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of
innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications,
such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are
quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales
entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through
acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros,
according to preliminary figures. Currently, more than 10,600 employees are working for customers around the globe.
Contact
Petra Kirchhoff; Head of Corporate Communications and Investor Relations
Phone: +49(0)551.308.1686; petra.kirchhoff@sartorius.com
Follow Sartorius Stedim Biotech on Twitter @Sartorius_Group and on LinkedIn.
=----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file
File: Sartorius Stedim Biotech: Information on Document Availability
=----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: sartorius.presse@sartorius.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext DIM
Ticker:
AMF Category: Additional regulated information to be pubicly disclosed under the legislation of a Member State / Terms
of availability of a registration document or its updates
EQS News ID: 1838837
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1838837 16-Feb-2024 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1838837&application_name=news
(END) Dow Jones Newswires
February 16, 2024 03:23 ET (08:23 GMT)
